Image

The Lymphocytic Infiltrate of Lung Tumors.

The Lymphocytic Infiltrate of Lung Tumors.

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The study is configured as a monocentric observational transversal biological study.

The main objective of the study is the reconstruction of the molecular organization of tumors of the thoracic cavity, in particular non-small cell lung cancer (NSCLC).

The study involves the collection of clinical data and biological material (blood and tumor tissue) from 70 subjects diagnosed with thoracic tumors.

Description

Inclusion criteria:

The study population will include all patients with the following characteristics:

  • Ability to provide informed consent
  • Men and women over the age of 18 years old
  • Patients candidates for surgical treatment diagnosed with thoracic tumors

The procedures to which the patient will undergo during the study follow the standard of clinical practice for the treatment of pathology.

Exclusion criteria:

  • Previous chemotherapy for any cancer within the last 6 months
  • Pregnant and/or breastfeeding women
  • Immunosuppressive state (states of immunosuppression or ongoing immunosuppressive/immunomodulatory treatments)

The time of observation of the patient for the purposes of the study is limited to the time of hospitalization and the surgical procedure, the patient will therefore perform a single visit to the hospital and there is no provision for the collection of further data following discharge. The study involves a single timepoint of data collection and samples.

The study will have a total duration of 3 years.

Eligibility

Inclusion Criteria:

  • Ability to provide informed consent;
  • Men and women over the age of 18;
  • Patients candidates for surgical treatment diagnosed with thoracic tumors

Exclusion Criteria:

  • Previous chemotherapy for any cancer within the last 6 months;
  • Pregnant and/or breastfeeding women;
  • Immunosuppressive state (states of immunosuppression or ongoing immunosuppressive/immunomodulatory treatments)

Study details
    Lung Cancer
    Immune System

NCT06470607

Scientific Institute San Raffaele

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.